Ida Hilden is currently the Corporate Vice President and head of BioPharm Rare Disease Research in Global Drug Discovery at Novo Nordisk.
Ida has previously worked in biotech, being involved in innovation and early drug development. She joined Novo Nordisk in 2004 and has led various research and development programs of new drug candidates for haemophilia treatment and other therapeutic areas. Since 2020, she has led the expansion of the rare blood and rare endocrine disease area in Global Drug Discovery.
Ida has an MSc in Biochemistry and holds a PhD in Protein Chemistry from the University of Copenhagen.